ABVC BioPharma, Inc. (ABVC) stock
ABVCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ECOC
$0.96−0.03 (-3.03%)
Close on Nov 12, 2026Market cap $25.59MP/E –Yield –
Earnings
ABVC BioPharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q3 FY2025
$1.28M
+228.8% on a year earlier
EPS, Q3 FY2025
–
-$0.02 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of ABVC BioPharma's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | Mar 3, 2026during market hours | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 3, 2025before the open | $1.28M | +228.8% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025before the open | – | – | -$0.13 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 15, 2025during market hours | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024before the open | $389.28K | +2350.7% | -$0.02 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 15, 2024before the open | $117.14K | – | -$0.09 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 14, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 15, 2023before the open | $15.88K | – | -$0.82 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 24, 2023before the open | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 3, 2023during market hours | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 31, 2023during market hours | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 31, 2022during market hours | – | – | – | Release |
| Q4 FY2014ended Sep 18, 2014 | Oct 24, 2014during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
ABVC BioPharma has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When ABVC BioPharma puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases ABVC BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Update
- Results
- Update
- Results
- BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateResults
- News
- Results
See a number that looks wrong?